ENVB stock forecast, quote, news & analysis
Enveric Biosciences Inc is a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, addiction, and other psychiatric disorders... Show more
Enveric Biosciences (ENVB) Stock Analysis: A Preclinical Neuroplastogen Developer Navigating a Tight Trading Range
Key Takeaways
- ENVB shares closed near $1.51, up roughly 9% from about $1.38 one month earlier, keeping the 30-day move below the 10% threshold.
- Trading has been range-bound, with the stock holding mostly between about $1.33 and $1.55 over the trailing 30 days.
- Enveric Biosciences is a clinical-stage biotechnology company advancing EB-003, a non-hallucinogenic neuroplastogen candidate for psychiatric and neurological disorders.
- The company reported a third-quarter net loss of $2.5 million and held approximately $5.6 million in cash as of September 30, 2026.
- With a market capitalization near $7 million and a small float, ENVB is prone to sharp, liquidity-driven price swings.
- Management is working toward an Investigational New Drug (IND) submission and a first-in-human Phase 1 trial for EB-003.
- For additional detail, explore the dedicated Price Targets, Earnings, and Forecast pages.
- Discover curated trading strategies on Trending AI Robots.
Current Market Snapshot
Enveric Biosciences (ENVB) trades on the Nasdaq Capital Market as a micro-cap development-stage company. As of mid-November 2026, shares were changing hands near $1.51, well below the stock's 52-week high of $13.25 and modestly above its 52-week low of $1.17. The company's market capitalization sits around $7 million, and its small float makes the stock sensitive to relatively modest changes in trading volume and investor sentiment.
Over the trailing 30 days, ENVB drifted within a comparatively narrow band, recovering from a late-October trough near $1.33 to close near $1.51. The move translates to a gain of roughly 9%, a modest advance that has not yet produced a decisive breakout. Average daily volume has remained thin, reinforcing the view that price action reflects both pipeline-related news flow and technical positioning rather than a broad institutional re-rating.
Enveric Biosciences (ENVB) Business Overview and Competitive Position
Enveric Biosciences is a biotechnology company focused on developing next-generation, small-molecule neuroplastogenic therapeutics for psychiatric and neurological disorders. Its lead candidate, EB-003, is designed to selectively engage both the 5-HT2A and 5-HT1B serotonin receptors, with the goal of delivering fast-acting and durable antidepressant and anxiolytic effects without the hallucinogenic experience associated with classical psychedelics.
The company's strategy centers on a differentiated drug-discovery platform and a growing library of protected chemical structures. By pursuing non-hallucinogenic neuroplastogens, Enveric aims to support simpler, outpatient-based treatment models that could broaden patient access and commercial adoption. Investors follow ENVB primarily for the progression of EB-003 toward clinical development, the expansion of its intellectual property portfolio, and the evolving regulatory framework for psychedelic-inspired therapies.
Recent Developments Driving ENVB
On November 13, 2026, Enveric reported financial results for the third quarter ended September 30, 2026. The company posted a net loss of $2.5 million, or $0.57 per share, and disclosed cash on hand of approximately $5.6 million. The report emphasized progress across the final IND-enabling activities for EB-003 ahead of a planned IND submission and first-in-human Phase 1 trial.
During the quarter, Enveric reported a preclinical qEEG study demonstrating evidence of central nervous system penetration and a brain-activity profile distinct from the classic psychedelic DMT. The company also announced positive results from IND-enabling in vitro ADMET studies indicating favorable absorption and metabolic properties with reduced potential for drug-drug interactions, and additional GloSensor assay data supporting EB-003's predicted non-hallucinogenic profile.
On the intellectual property front, Enveric secured a U.S. patent allowance covering next-generation, non-hallucinogenic mescaline derivatives in its EVM401 series. The company also highlighted the U.S. Food and Drug Administration's finalized guidance for clinical investigations of psychedelic and psychedelic-inspired therapeutics, a development management views as supportive of the broader neuroplastogen field.
Trending AI Robots
Tickeron's Trending AI Robots page showcases a curated selection of AI-powered trading bots drawn from a much larger platform that features hundreds of bots trading thousands of tickers. Only the top-performing and most relevant strategies are surfaced in this section, giving traders a focused view of approaches that are currently gaining traction. The bots span a wide range of strategies, timeframes, and performance metrics, so the section can serve as a useful starting point for comparing systematic approaches without committing to any single style. Visitors can browse the available bots to evaluate how different algorithms are positioned across the market.
2026 Outlook and What Investors Should Watch
The primary catalyst on Enveric's near-term horizon is the planned IND submission for EB-003 and the subsequent initiation of a first-in-human Phase 1 trial. Any updates on trial design, enrollment timelines, or additional safety and biomarker data are likely to influence sentiment in a stock with limited institutional coverage.
Investors are also monitoring the company's balance sheet. With approximately $5.6 million in cash as of September 30, 2026, financing activity and potential dilution remain key considerations for a pre-revenue developer. Macroeconomic conditions and risk appetite for speculative biotech names can further amplify moves in a low-float security.
Finally, the broader regulatory environment for psychedelic-inspired therapeutics continues to evolve. FDA guidance, competitive developments across the neuroplastogen space, and the pace at which Enveric converts its expanding patent portfolio into clinical milestones will all shape the stock's trajectory. As always, these factors should be weighed against the inherent risks of early-stage drug development.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
ENVB's MACD Histogram crosses above signal line
The Moving Average Convergence Divergence (MACD) for ENVB turned positive on October 28, 2026. Looking at past instances where ENVB's MACD turned positive, the stock continued to rise in 37 of 43 cases over the following month. The odds of a continued upward trend are 86%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 51 of 66 cases where ENVB's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 77%.
The Momentum Indicator moved above the 0 level on November 06, 2026. You may want to consider a long position or call options on ENVB as a result. In 70 of 91 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 77%.
ENVB moved above its 50-day moving average on November 10, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for ENVB crossed bullishly above the 50-day moving average on November 13, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 9 of 12 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 75%.
Following a +4.90% 3-day Advance, the price is estimated to grow further. Considering data from situations where ENVB advanced for three days, in 139 of 183 cases, the price rose further within the following month. The odds of a continued upward trend are 76%.
ENVB may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ENVB declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for ENVB entered a downward trend on October 28, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 1 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.797) is normal, around the industry mean (3.498). P/E Ratio (-0.118) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). ENVB's Dividend Yield (51359.711) is considerably higher than the industry average of (130.981). P/S Ratio (0.000) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 63 (best 1 - 100 worst), indicating steady price growth. ENVB’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 100 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ENVB’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a provider of technology management solutions services
Industry Biotechnology